Genmab — April 2020

[JKY_VH]

helt enig, han er outstanding.

[Solsen]

Det er JNJs sidste chance før det bliver alt for dyrt.

[Bulder]

sgen kører da med klatten. Allerede tilbage pænt over præcorona-niveau. Gad vide om det er sc-dara, der bonger ud.

[Bulder]

sludder glem det. det er ikke sgen

[GeorgeBest]

sgen negative estimeret eps på USD -0,99. market cap 21B USD. de må have andet end TV i pipeline for fremtidig indtjening....

[Legolas23]

Fin stigning i de døende minutter. Får vi en fin nyhed i løbet af aftenen?

[Solsen]

Bulder dog

[Solsen]

Vi skal have Genmab op i samme værdi som SGEN.

[Bulder]

jarh, kom til at rode rundt i sgen og halo. Men spøjst som sgen vinder frem. Har de noget af corona-interesse?

[Solsen]

Nope

[Solsen]

Men det er snart ikke til at holde styr på. SGENs hovedprodukt Acetris, mener jeg Genmab kan have en ejerandel i et bedre produkt gennem ADC Therapeutics ADCT-301

[Solsen]

Adcetris - Brentuximab vedotin

[E_L]

amivantamab in phase II according this JNJ slide https://twitter.com/semodough/status/1250827516161527810/photo/1

[peter12]

I think it has been phase2 since dec 2018 ? At least according to other sources. There is a part 2 to the study https://clinicaltrials.gov/ct2/show/NCT02609776 Originally it was n=180 ?

[Plimsoller]

God morgen

[transalp]

Go morgen..

[bibob]

God morgen.

[GeorgeBest]

Genmab A/S (NASDAQ:GMAB) - SunTrust Banks boosted their FY2020 EPS estimates for shares of Genmab A/S in a research note issued to investors on Tuesday, April 14th. SunTrust Banks analyst A. Goonewardene now forecasts that the company will earn $0.24 per share for the year, up from their previous estimate of $0.23. SunTrust Banks has a "Buy" rating on the stock. SunTrust Banks also issued estimates for Genmab A/S's FY2022 earnings at $0.80 EPS and FY2023 earnings at $1.01 EPS.

[GeorgeBest]

GMAB has been the topic of a number of other research reports. Zacks Investment Research raised shares of Genmab A/S from a "sell" rating to a "hold" rating in a research report on Thursday, February 27th. HC Wainwright reduced their price target on Genmab A/S from $29.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday. Royal Bank of Canada reiterated a "buy" rating and issued a $27.00 target price on shares of Genmab A/S in a report on Monday, April 6th. Final

[GeorgeBest]

Finally, Morgan Stanley lowered their price objective on Genmab A/S from $31.00 to $30.00 and set an "overweight" rating for the company in a research report on Wednesday. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has an average rating of "Buy" and a consensus target price of $27.00.